+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Prognostic and putative predictive biomarkers of gastric cancer for personalized medicine

Prognostic and putative predictive biomarkers of gastric cancer for personalized medicine

Diagnostic Molecular Pathology 22(3): 127-137

We investigated various phenotypic and genotypic biomarkers of gastric cancer (GC) testing the following hypotheses: are these biomarkers suitable for the identification of GC subtypes, are they of prognostic significance, and should any of these biomarkers be considered to tailor patient treatment in the future. The study cohort consisted of 482 patients. pTNM-stage was based on surgical pathologic examination. The Laurén and mucin phenotype was assessed. Helicobacter pylori and Epstein-Barr virus infections were documented. The following biomarkers were determined: BRAF, KRAS, NRAS, and PIK3CA genotype, microsatellite instability, mucin 1, mucin 2, mucin 5, and mucin 6, CD10, E-cadherin, β-catenin, and lysozyme. The histologic phenotype correlated with 10/13 (77%) clinicopathologic patient characteristics and 6/13 (46%) immunohistochemical/molecular biological biomarkers. Inversely, immunohistochemical biomarkers (mucin phenotype, E-cadherin, β-catenin, and lysozyme) were unsuitable for subclassification of GC. It showed too much overlap between the different subtypes. Among the genotypes, only microsatellite instability correlated with tumor type being more prevalent in intestinal and unclassified GCs. Patient survival correlated significantly with 8 (62%) clinicopathologic and 5 (36%) immunohistochemical/molecular biomarkers. Interestingly, in proximal GCs, KRAS mutation was associated with worse prognosis, as was persistent H. pylori infection in unclassified GCs. Mucin 2 (all patients, proximal GCs) and PIK3CA (exon 20; intestinal type GC) prognosticated independently patient survival. The biomarkers examined herein are unsuitable to aid histologic classification of GC. However, several of them show a correlation with either phenotype and/or prognosis and may be considered to tailor patient treatment in the future, such as KRAS, PIK3CA, MSI, and H. pylori status.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 055209213

Download citation: RISBibTeXText

PMID: 23846438

DOI: 10.1097/pdm.0b013e318284188e

Related references

Predictive biomarkers for targeted and cytotoxic agents in gastric cancer for personalized medicine. Bioscience Trends 10(3): 171-180, 2016

Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment. Journal of Gastrointestinal Oncology 8(3): 405-417, 2017

Personalized medicine: the search for prognostic and predictive factors in colorectal cancer. Journal of Laboratory and Clinical Medicine 142(1): 5-6, 2003

Predictive and prognostic markers in the treatment of metastatic colorectal cancer (mCRC): personalized medicine at work. Hematology/Oncology Clinics of North America 29(1): 43-60, 2015

Synergistic role between p53 and JWA: prognostic and predictive biomarkers in gastric cancer. Plos one 7(12): E52348, 2012

Biomarkers for gastric cancer: prognostic, predictive or targets of therapy?. Virchows Archiv 464(3): 367-378, 2014

Prognostic and predictive biomarkers: tools in personalized oncology. Molecular Diagnosis and Therapy 18(3): 273-284, 2014

Prognostic Value of Inflammatory Biomarkers in Gastric Cancer Patients and the Construction of a Predictive Model. Digestive Surgery 36(5): 433-442, 2019

How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer. Oncologist 19(10): 1046-1055, 2014

Diagnostic, Predictive, Prognostic, and Therapeutic Molecular Biomarkers in Third Millennium: A Breakthrough in Gastric Cancer. Biomed Research International 2017: 7869802, 2017

Prognostic and predictive biomarkers in adult and pediatric gliomas: toward personalized treatment. Frontiers in Oncology 4: 47, 2014

Prognostic value of pre-operative inflammatory response biomarkers in gastric cancer patients and the construction of a predictive model. Journal of Translational Medicine 13: 66, 2015

Prognostic and predictive blood biomarkers in gastric cancer and the potential application of circulating tumor cells. World Journal of Gastroenterology 24(21): 2236-2246, 2018

Discovery of biomarkers in rare diseases: innovative approaches by predictive and personalized medicine. Epma Journal 7: 24, 2016

Predictive and on-treatment monitoring biomarkers in advanced melanoma: Moving toward personalized medicine. Cancer Treatment Reviews 71: 8, 2018